Journal ArticleOPEN ACCESS

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

  • Castellino S
  • Pei Q
  • Parsons S
  • et al.
New England Journal of Medicine (2022) 387(18) 1649-1660
DOI: 10.1056/nejmoa2206660
130Citations
Citations of this article
115Readers
Mendeley users who have this article in their library.

Abstract

Abstract Background In adults with advanced-stage Hodgkin’s lymphoma, the CD30-directed antibody–drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have grea...

Cite

CITATION STYLE

APA

Castellino, S. M., Pei, Q., Parsons, S. K., Hodgson, D., McCarten, K., Horton, T., … Kelly, K. M. (2022). Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma. New England Journal of Medicine, 387(18), 1649–1660. https://doi.org/10.1056/nejmoa2206660

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free